Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Reliability of estimated glomerular filtration rate in patients treated with platinum containing therapy

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Nefrologisk afd P Rigshospitalet test.

    Project: Types of projects

  1. Testicular cancer incidence predictions in Europe 2010–2035: A rising burden despite population ageing

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tibolone and risk of gynecological hormone sensitive cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Does HPV status influence survival after vulvar cancer?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Luteinizing Hormone Receptor Is Expressed in Testicular Germ Cell Tumors: Possible Implications for Tumor Growth and Prognosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prospective molecular and morphological assessment of testicular prepubertal-type teratomas in postpubertal men

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Estimates of glomerular filtration rate (eGFR) are widely used when administering nephrotoxic chemotherapy. No studies performed in oncology patients have shown whether eGFR can safely substitute a measured GFR (mGFR) based on a marker method. We aimed to assess the validity of four major formulas based on PCr (Cockcroft-Gault, MDRD, Wright and CKD-EPI) in comparison to mGFR in an oncology setting. Patients included had disseminated germ cell cancer and received conventional chemotherapy: bleomycin, etoposide and cisplatin. The mGFR of the patients was compared to all estimates with focus on bias (median percentage error), precision (median absolute percentage error) and accuracy (p10 and p30). The precision of carboplatin dosage based on eGFR was calculated. Data on mGFR, eGFR, and PCr were available in 390 patients, with a total of ∼ 1,600 measurements. Median PCr and mGFR synchronically decreased after chemotherapy, yielding high bias and low precision of most estimates. Post-chemotherapy, bias ranged from -0.2% (MDRD after four cycles) to 33.8% (CKD-EPI after five cycles+), precision ranged from 11.6% (MDRD after four cycles) to 33.8% (CKD-EPI after five cycles+) and accuracy (p30) ranged from 37.5% (CKD-EPI after five cycles+) to 86.9% (MDRD after four cycles). Although MDRD appeared acceptable after chemotherapy because of high accuracy, this equation underestimated GFR in all other measurements. Before and years after treatment, Cockcroft-Gault and Wright offered best results. Precision of carboplatin dosage was low. In conclusion, bias, precision and accuracy were unacceptable in all equations due to a synchronous decrease of PCr and mGFR during chemotherapy.

Original languageEnglish
JournalInternational journal of cancer. Journal international du cancer
Volume135
Issue number7
Pages (from-to)1733-9
Number of pages7
ISSN0020-7136
DOIs
Publication statusPublished - 1 Oct 2014

    Research areas

  • Adult, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Pharmacological, Bleomycin, Carboplatin, Cisplatin, Creatinine, Etoposide, Follow-Up Studies, Glomerular Filtration Rate, Humans, Kidney Diseases, Male, Neoplasms, Germ Cell and Embryonal, Prognosis, Reproducibility of Results

ID: 44873872